Feature | Cath Lab | May 18, 2020

Eating Prior to Cardiac Cath Noninferior to Fasting in CHOW NOW Study 

No restriction of oral intake deemed just as safe as traditional NPO strategy

Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020

May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols. The single center, randomized study was presented as late-breaking science during the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Virtual Conference aimed to compare safety and clinical outcomes of a non-fasting (NF) strategy as compared to current standard fasting (SF) protocol. 

The CHOW NOW study is the first in the United States and globally with a large number of randomized patients evaluating the safety of letting them eat prior to a non-emergent cardiac catheterization. This study was performed at Guthrie Robert Packer Hospital in Sayre, Penn.

“This study really challenges one of the established practices of having the patients fast prior to a non-emergent cardiac catheterization procedure,” said Abhishek Mishra, M.D., lead study investigator and cardiologist at Vidant Heart and Vascular Institute-North Carolina. “This practice has been in place for [several] decades without having any actual evidence to support it. With advancement of procedural technology and moderate conscious sedation, the perceived risk of complications has significantly reduced,” Mishra continued.

The SF group was instructed to be NPO after midnight but could have clear liquids up to two hours before the procedure. The NF group had no restriction on oral intake irrespective of time of the cardiac catheterization. Primary outcomes included a composite of contrast induced nephropathy (CIN), peri-procedural hypotension, aspiration pneumonia, nausea/vomiting, hypoglycemia and hyperglycemia. Secondary outcomes included assessment of patient satisfaction, in-patient mortality and total cost of index hospitalization.
A total of 599 patients (outpatients: n=305, inpatients: n=294) were randomized. Both groups had similar baseline characteristics. As compared to the SF group (n=306), NF group (n=293) had similar rates of primary outcome (9.8 vs. 11.3% respectively, p=0.65) and was non-inferior to the fasting strategy at a threshold of 0.059. 

There was no significant difference in incidence of CIN (1.6 vs. 2.4%), peri-procedural hypotension (1.6% vs. 2%), aspiration pneumonia (none vs. 0.7%), nausea/vomiting (3.6% vs 5.1%), hyperglycemia (3.3% vs. 1.4%), or hypoglycemia (1% in both). More than 99% patients of both groups were discharged alive. 

There was no significant difference with regards to the patient satisfaction score and 30-day mortality. [fasting vs NF: 4.38±0.90 vs. 4.49±0.77 and 1.3 vs. 2.4% respectively, p=ns for both]. Cost of hospitalization was also similar in both groups.

“We hope that the findings of this study help make the cardiac catherization procedure more 'patient centered',” stated Mishra. “The current fasting practice does result in more discomfort and frustration for the patients who may sometimes end up waiting several hours longer than the planned 6 hours of fasting. Imagine a diabetic patient who is fasting for a procedure overnight, only to realize that there has been an emergent procedure scheduled prior to him at the last minute and he may end up having the procedure later in the day, when he may already be fasting for nearly 14+ hours. Also, patient contentedness being a focus of healthcare in current practice, this study is an important step to maximize patient comfort in a safe manner.”

Mishra stated that fasting practices currently differ based on the institutional policy and hopes that the study will provide evidence which can be incorporated into future professional society guidelines.

Find links to the rest of the SCAI late-breaking trials and other SCAI news

 

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme